Skeletal muscle atrophy is a wide-spreading and debilitating pathophysiological condition that accompanies a substantial personal and economic burden. Remarkably, despite its prevalence, very few treatment options are available for muscle wasting. Mechanistic studies have shown that activin type 2 receptors (ActRIIA/B) and their ligands are potent regulators of muscle atrophy, and their inhibition has the potential to attenuate, and even reverse muscle loss. Here, we present a novel active immunotherapy approach for inhibiting these receptors using virus-like particle vaccines. We demonstrate that the vaccines generate high titer levels and exhibit a high binding capacity and specificity against both ActRIIA and ActRIIB.
Cookie SettingseScholarship uses cookies to ensure you have the best experience on our website. You can manage which cookies you want us to use.Our Privacy Statement includes more details on the cookies we use and how we protect your privacy.